Advent Capital Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Advent Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,390	Closed	-$42K	–	252
2018 Q4	$42K	Buy	+1,390	New	+$28.5K	﹤0.01%	198
2018 Q1	–	Sell	-750	Closed	-$6K	–	302
2017 Q4	$6K	Buy	750 +450	+150%	+$6.77K	﹤0.01%	250
2017 Q3	$2K	Buy	+300	New	+$6.75K	﹤0.01%	286
2016 Q1	–	Sell	-150	Closed	-$1K	–	488
2015 Q4	$1K	Buy	+150	New	+$9.27K	﹤0.01%	459

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Advent Capital Management's TEVA Position: Q4 2017 in Review

Advent Capital Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q4 2017, closing a stake of 50,000 shares — an estimated $752K sold.

Advent Capital Management first reported a position in TEVA in Q3 2017 and held it in 1 quarter. The position peaked at $880K in Q3 2017. 508 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

Advent Capital Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q4 2017 after selling out during the quarter.
Advent Capital Management sold 50,000 Teva Pharmaceutical Industries Limited shares in Q4 2017, an estimated $752K.
Advent Capital Management first reported a position in Teva Pharmaceutical Industries Limited in Q3 2017 and held it in 1 quarter.
Advent Capital Management's Teva Pharmaceutical Industries Limited position peaked at $880K in Q3 2017.
508 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q4 2017.

Based on Advent Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.